SAHRANG: Subarachnoid Hemorrhage Recovery and Galantamine: A Pilot Multicenter Randomized Placebo-Controlled Trial
Galantamine was as tolerable and safe as a placebo based on discontinuation rates and mortality in patients with SAH when administered to patients with SAH during the early and subacute stages of the disease.
Authors
- H. Alex Choi (ORCID: https://orcid.org/0000-0001-7218-832X)
- Georgene W. Hergenroeder (ORCID: https://orcid.org/0000-0002-6170-2191)
- Sophie Samuel (ORCID: https://orcid.org/0000-0003-2544-900X)
- James C. Grotta (ORCID: https://orcid.org/0000-0002-3667-4248)
- Andrew D. Barreto (ORCID: https://orcid.org/0000-0003-1694-0059)
- Bosco Seong Kyu Yang (ORCID: https://orcid.org/0000-0002-2287-3684)
- Claudia Pedroza (ORCID: https://orcid.org/0000-0003-4235-1282)
- Kevin E. Immanuel
- Jude P. J. Savarraj (ORCID: https://orcid.org/0000-0003-0194-0734)
- Glenda Torres
- Jung Hwan Kim (ORCID: https://orcid.org/0000-0003-0639-0428)
- Elena Nieto Moreno
Institutions
- Methodist Hospital (US)
- The University of Texas Health Science Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Neurocritical Care
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1007/s12028-025-02349-3
- Primary Topic
- Intracranial Aneurysms: Treatment and Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
- National Institute of Neurological Disorders and Stroke